Stanley Laman Group, Ltd. Regenxbio Inc. Transaction History
Stanley Laman Group, Ltd.
- $676 Million
- Q1 2024
Shares
1 transactions
Others Institutions Holding RGNX
# of Institutions
193Shares Held
42.1MCall Options Held
80.6KPut Options Held
55.2K-
Black Rock Inc. New York, NY7.6MShares$80.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.88MShares$51.8 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.55MShares$48.4 Million3.78% of portfolio
-
Jpmorgan Chase & CO New York, NY3.72MShares$39.6 Million0.01% of portfolio
-
State Street Corp Boston, MA3.12MShares$33.2 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $460M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...